VYNE Share Price | VYNE Therapeutics, Inc. Stock Analysis & Recommendation

Q: What does VYNE Therapeutics, Inc. do?

Overview: VYNE Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for pruritus associated with dermatologic conditions, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.Financial Snapshot: Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) Most recent Net Profit: -9 Million (Quarterly Results - Mar 2025) Market cap: USD 15.31 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.14 Return on Equity: -95.55% Price to Book: 0.35Contact Details: Address: 520 U.S. Highway 22, Suite 204, BRIDGEWATER NJ: 08807 Tel: 1 650 4861416 Fax: 1 302 6555049 Website: http://www.menlotherapeutics.com/

Q: Is VYNE Therapeutics, Inc. overvalued or undervalued?

As of 9 March 2023, the valuation grade for VYNE Therapeutics, Inc. has moved from risky to does not qualify, indicating significant concerns about its financial health. The company appears to be overvalued given its current metrics, particularly with a price to book value of 0.38 and an EV to EBITDA ratio of 0.74. Notably, the return on equity (ROE) stands at a concerning -95.55%, which further supports the notion of overvaluation.In comparison to its peers, VYNE Therapeutics has a less favorable position, with NanoViricides, Inc. and Mangoceuticals, Inc. also classified as does not qualify, but with EV to EBITDA ratios of -2.0886 and -2.0415, respectively. The company's recent stock performance has been dismal, with a year-to-date return of -72.71%, contrasting sharply with the S&P 500's gain of 2.44%. Overall, these indicators suggest that VYNE Therapeutics is overvalued in the current market environment.

Q: Is VYNE Therapeutics, Inc. technically bullish or bearish?

As of 5 August 2025, the technical trend for VYNE Therapeutics, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength. Key indicators driving this include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a bearish KST across both weekly and monthly periods. The Bollinger Bands indicate a mildly bearish trend on the weekly and bearish on the monthly. Additionally, the Dow Theory shows a bearish trend on the monthly, while the OBV is mildly bearish on the monthly. In terms of performance, VYNE has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -90.75% compared to the S&P 500's 12.22%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

66.71 k

Shareholding (Sep 2025)

FII

1.23%

Held by 8 FIIs

DII

90.19%

Held by 6 DIIs

Promoter

4.14%

How big is VYNE Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, VYNE Therapeutics, Inc. has a market capitalization of 15.31 million and reported net sales of 0.60 million with a net profit of -42.16 million over the latest four quarters. Shareholder's funds are 52.09 million, and total assets amount to 66.91 million.

View full answer

What does VYNE Therapeutics, Inc. do?

22-Jun-2025

VYNE Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for pruritus related to dermatologic conditions, with a market cap of $15.31 million and recent net sales of $0 million. The company is currently operating at a loss, with a net profit of -$9 million as of March 2025.

View full answer

Who are in the management team of VYNE Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of VYNE Therapeutics, Inc. includes CEO David Domzalski, Directors Sharon Barbari, Rex Bright, Anthony Bruno, Independent Directors Patrick LePore and Elisabeth Sandoval, who oversee the company's strategic direction and operations.

View full answer

Is VYNE Therapeutics, Inc. overvalued or undervalued?

25-Jun-2025

As of March 9, 2023, VYNE Therapeutics, Inc. is considered overvalued with significant financial concerns, reflected in a price to book value of 0.38, an EV to EBITDA ratio of 0.74, a troubling -95.55% return on equity, and a year-to-date stock performance decline of -72.71%.

View full answer

Is VYNE Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of August 5, 2025, VYNE Therapeutics, Inc. is in a bearish trend with weak strength, indicated by bearish MACD, moving averages, and KST, while significantly underperforming the S&P 500 with a year-to-date return of -90.75%.

View full answer

Compare VYNE Therapeutics, Inc. with Similar Stocks

RVL Pharmaceuticals Plc Moleculin Biotech, Inc.Eiger BioPharmaceuticals, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 19 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.02

Return on Equity

-105.30%

Price to Book

0.60

Revenue and Profits:

Net Sales:

0 Million

(Quarterly Results - Jun 2025)

Net Profit:

-6 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-71.87%

6 Months

-78.91%

1 Year

-75.57%

2 Years

-89.43%

3 Years

-93.57%

4 Years

-99.24%

5 Years

-99.63%

VYNE Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-48.65%

EBIT Growth (5y)

9.55%

EBIT to Interest (avg)

-28.37

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.14

Sales to Capital Employed (avg)

0.01

Tax Ratio

0.01%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

45.51%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.38

EV to EBIT

0.74

EV to EBITDA

0.74

EV to Capital Employed

5.52

EV to Sales

-33.54

PEG Ratio

Dividend Yield

ROCE (Latest)

747.97%

ROE (Latest)

-95.55%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

Bearish

Bullish

Bollinger Bands

Mildly Bullish

Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 5 Schemes (4.44%)

Foreign Institutions

Held by 8 Foreign Institutions (1.23%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -50.00% vs 100.00% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 33.72% vs 28.33% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-7.50",
          "val2": "-9.20",
          "chgp": "18.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.70",
          "val2": "-8.60",
          "chgp": "33.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-109,304.30%",
          "val2": "-45,529.70%",
          "chgp": "-6,377.46%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 25.00% vs -20.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -42.65% vs 17.70% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.50",
          "val2": "0.40",
          "chgp": "25.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-43.60",
          "val2": "-29.30",
          "chgp": "-48.81%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-39.80",
          "val2": "-27.90",
          "chgp": "-42.65%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-87,099.80%",
          "val2": "-69,004.70%",
          "chgp": "-1,809.51%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.10

0.20

-50.00%

Operating Profit (PBDIT) excl Other Income

-7.50

-9.20

18.48%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-5.70

-8.60

33.72%

Operating Profit Margin (Excl OI)

-109,304.30%

-45,529.70%

-6,377.46%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -50.00% vs 100.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is 33.72% vs 28.33% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.50

0.40

25.00%

Operating Profit (PBDIT) excl Other Income

-43.60

-29.30

-48.81%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-39.80

-27.90

-42.65%

Operating Profit Margin (Excl OI)

-87,099.80%

-69,004.70%

-1,809.51%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 25.00% vs -20.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -42.65% vs 17.70% in Dec 2023

All Annual Results

Company CV

About VYNE Therapeutics, Inc.

VYNE Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Vyne Therapeutics Inc., formerly Menlo Therapeutics Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of serlopitant for the treatment of pruritus (itch) associated with dermatologic conditions, such as atopic dermatitis, psoriasis and prurigo nodularis. The Company is focused on developing and commercializing a variety of solutions using its Molecule Stabilizing Technology (MST). The Company has a commercial-stage product, AMZEEQ, and several late-stage product candidates. It is also evaluating the use of serlopitant for the treatment of refractory chronic cough. The Company’s serlopitant is a small molecule, highly selective NK1-R antagonist. It is developing serlopitant as a once-daily oral tablet therapy.

Company Coordinates

Company Details

520 U.S. Highway 22, Suite 204 , BRIDGEWATER NJ : 08807

Tel: 1 650 4861416

http://www.menlotherapeutics.com/

Registrar Details

VYNE Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is VYNE Therapeutics, Inc.?

Watch in Real-Time

What does VYNE Therapeutics, Inc. do?

Who are in the management team of VYNE Therapeutics, Inc.?

Is VYNE Therapeutics, Inc. overvalued or undervalued?

Is VYNE Therapeutics, Inc. technically bullish or bearish?

Compare VYNE Therapeutics, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About VYNE Therapeutics, Inc.

Company Coordinates